Although there has been a concentrated focus on pulmonary vascular diseases at this year's CHEST conference, there have also been a number of studies released that pertain to cardiovascular events, such as congestive heart failure, atrial fibrillation, and chronic obstructive pulmonary disease. Here are some of the highlights in these areas.
Although there has been a concentrated focus on pulmonary vascular diseases at this year’s CHEST conference, there have also been a number of studies released that pertain to cardiovascular events, such as congestive heart failure, atrial fibrillation, and chronic obstructive pulmonary disease. Here are some of the highlights in these areas.
Carlin et al presented the information from their study, Rehospitalization Rates and Clinical Characteristics of Patients Enrolled in a Transition of Care Program Following Hospitalization for Congestive Heart Failure, which evaluated the outcomes of a home-care based, respiratory therapist-centered transition of care program on rehospitalization rates for patients hospitalized with congestive heart failure (CHF) that require supplemental oxygen following hospital discharge. The researchers also examined the clinical characteristics of patients that were enrolled in the program. The methods in this study included face-to-face visits on days 2, 7, and 30 following hospital discharge and a series of care coordinator phone interviews. Additionally, 30-day readmission rates following discharge were captured and data were collected from March 2010 to March 2012. Following an analysis of their results, the study authors concluded that “a patient-centered transition of care program can be successfully used to help reduce the 30-day readmission rates for patients following hospitalization for an exacerbation of their underlying CHF.”
For additional discussion on the challenges related to reducing readmission rates, check out AJMC’s video interview with Dr Brian Carlin.
Nessel et al released the information for their study, Incidence and Outcomes of Gastrointestinal Hemorrhage in Patients With Atrial Fibrillation Treated With Rivaroxaban or Warfarin: Results From the ROCKET AF Trial. Because gastrointestinal hemorrhage (GI) is a common complication of anticoagulant therapy, the study authors aimed to investigate the incidence and outcomes of GI hemorrhage among patients in the ROCKET AF study. The ROCKET AF study included 14,264 patients with nonvalvular atrial fibrillation who were randomized to receive rivaroxaban or dose-adjusted warfarin. Following the analysis, the research team reported that “both major and non-major, clinically relevant GI bleeding were more common in patients with AF taking rivaroxaban than warfarin,” and that “there were fewer fatal GI bleeds on rivaroxaban and the absolute fatality rate was very low.”
Agarwal et al presented the findings from their study, Cardiovascular Disease Profile of Patients With Chronic Obstructive Pulmonary Disease: Results From the National Health and Nutrition Examination Survey (NHANES). The study compared the prevalence of cerebrovascular disease (CCVD) between chronic obstructive pulmonary disease (COPD) and non-COPD subjects. Additionally, among subjects without pre-existent CCVD, the study authors compared the short-term (10-year) and lifetime risk of development of CCVD in the 2 study groups. They observed “a significantly increased prevalence of CCVD among subjects with COPD,” and“among subjects without pre-existent CCVD, the risk of developing CCVD in the future was significantly higher in the COPD group as compared to the non-COPD group.”
To read more about research highlights at CHEST 2012, please visit the American College of Chest Physicians website.
POSITIVE Trial Update on Patients With Breast Cancer Attempting Pregnancy
December 8th 2023At last year’s San Antonio Breast Cancer Symposium, POSITIVE trial primary outcome data were presented on breast cancer–free interval, with women who paused endocrine therapy to attempt pregnancy having a similarly small rate of recurrence vs external controls from the SOFT and TEXT trials: 8.9% vs 9.2%.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
Negotiations to extend US global HIV/AIDS relief work are deadlocked; the Biden administration delayed its rule on the proposed menthol cigarette ban until March 2024 after lobbying by civil rights groups; federal agencies have partnered with a digital health company to create an at-home test-to-treat program for flu and COVID-19.
Read More